Perceptive Xontogeny Venture — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Avenge Bioavengebio.comJan 2022 · $45M

Biotechnology company developing the LOCOcyte cell-therapy platform for local dosing of immunotherapeutics.

Co-investorsLongitude Capital Pappas Capital Rock Springs Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.